Stay updated with breaking news from Teatosis hepatis. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Data on the investigative, temporary gut liner, EndoBarrier, showed improvement in weight, A1c, fatty liver, and need for insulin, and the effect persisted for up to 2 years after its removal. ....
Shares in Zealand Pharma soared 34% on Monday after an experimental weight-loss drug it is developing with Boehringer Ingelheim yielded what they called "groundbreaking". ....
Investigators from the ongoing MAESTRO-NASH trial provided more evidence that resmetirom may be a viable option in a disease state currently without any approved treatments. ....
Sagimet Biosciences said on Monday its experimental drug to treat a fatty liver disease significantly reduced the symptoms in a mid-stage study, sending the drug maker's. ....